MEMPHASYS LIMITED. — Capital/Financing Update 2024

Oct 17, 2024

ASX Release 18 October 2024

==> picture [152 x 42] intentionally omitted <==

ASX Code: MEM

Update to disclosure in Supplementary Prospectus – Placement participation

In the Company’s supplementary prospectus dated 20 September 2024 ( Supplementary Prospectus ), the Company disclosed that former director and substantial shareholder, Mr Andrew Goodall, is proposed to subscribe for a maximum of $150,000 worth of ordinary shares under the Placement.

Following agreement with the Lead Manager, Mr Goodall has been relieved of his obligations under his binding commitment letter and will no longer participate in the Placement.

Mr Goodall’s $150,000 allocation under the Placement has been reallocated to other sophisticated and professional investor clients of the Lead Manager (none of whom are related parties or substantial shareholders of the Company).

The level of binding commitments received for the Placement remains at $1 million.

This announcement has been approved for release by the board of Memphasys Limited.

ENDS

For further information, please contact:

Dr David Ali Andrew Metcalfe Managing Director / Chief Executive Officer Company Secretary Memphasys Limited Memphasys Limited Tel: +61 2 8415 7300 Tel: +61 412 125 090 E: david.ali@memphasys.com E: andrew@accosec.com

About Memphasys

Memphasys Limited (ASX: MEM) specialises in reproductive biotechnology for high value commercial applications. Reproductive biotechnology products in development include medical devices, in vitro diagnostics, and new proprietary media. The Company’s patented bioseparation technology, utilised by the Company’s most advanced product, the Felix™ System, combines electrophoresis with proprietary size exclusion membranes to separate the most viable sperm cells for human artificial reproduction.

Website: www.memphasys.com

The Felix™ System is a registered trademark of Memphasys Limited. All rights reserved.